Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
23 März 2022 - 2:39PM
Edgar (US Regulatory)
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of March 2022
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
23 March 2022 11:00 GMT
Notice of Annual General Meeting
AstraZeneca PLC (the Company) announced today the publication of
its Notice of Annual General Meeting 2022 and Shareholders'
Circular (the Notice).
The Notice and the proxy form for the Annual General Meeting (AGM)
have been submitted to the National Storage Mechanism and will
shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
The Notice is also available on the Company's website
at www.astrazeneca.com/noticeofmeeting2022.
The Company's Annual Report and Form 20-F Information 2021 (the
Annual Report) was published on 22 February 2022.
The Notice is being despatched to shareholders today.
The meeting place for the AGM will be the Royal Lancaster London
Hotel, Lancaster Terrace, London W2 2TY and the AGM will commence
at 2.30 pm (BST) on 29 April 2022.
At the time of issuing the Notice, there are no restrictions in the
UK relating to COVID-19 that would prevent the AGM going ahead or
significantly affect the arrangements for the meeting. If
circumstances change before the date of the AGM, the Board may be
required or may decide to alter the arrangements for the meeting to
ensure the health and safety of those present at the meeting. Any
alterations to the arrangements will be advertised on the Company's
website, www.astrazeneca.com,
and where appropriate by stock exchange
announcement.
The business to be conducted at the AGM is summarised
below:
1.
To receive the Company's Accounts, the Reports of the Directors and
Auditor and the Strategic Report for the year ended 31 December
2021
2.
To confirm dividends
3.
To reappoint PricewaterhouseCoopers LLP as Auditor
4.
To authorise the Directors to agree the remuneration of the
Auditor
5.
To elect or re-elect Directors
6.
To approve the Annual Report on Remuneration for the year ended 31
December 2021
7. To
authorise limited political donations
8.
To authorise the Directors to allot shares
9.
To authorise the Directors to disapply pre-emption
rights
10.
To authorise the Directors to further disapply pre-emption rights
for acquisitions and specified capital investments
11.
To authorise the Company to purchase its own shares
12.
To reduce the notice period for general meetings
13.
To extend the AstraZeneca 2012 Savings Related Share Option
Scheme
Pursuant to Regulation 41 of the Uncertificated Securities
Regulations 2001, only holders of ordinary shares entered in the
register of members of the Company by 6.30pm (BST) on 27 April 2022
(or their duly appointed proxies), or if this meeting is adjourned,
in the register of members by 6.30pm (BST) two days prior to any
adjourned meeting, are entitled to attend or vote at the AGM in
respect of the number of ordinary shares registered in their name
at that time. Changes to the entries in the register of members
after 6.30pm (BST) on 27 April 2022, or if this meeting is
adjourned, in the register of members after 6.30pm (BST) two days
prior to any adjourned meeting, shall be disregarded in determining
the rights of any person to attend or vote at the
AGM. The
Record Date applied to the Euroclear Sweden system to determine
entitlement to attend and vote at the AGM is close of business on
19 April 2022.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory
& Immunology. Based in Cambridge, UK, AstraZeneca operates
in over 100 countries and its innovative medicines are used by
millions of patients worldwide. Please
visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
23 March 2022
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|
AstraZeneca (NYSE:AZN)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
Von Apr 2023 bis Apr 2024
